2024-02-02 16:49:38 ET
More on Cytokinetics
- Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
- Cytokinetics: Clear Win For Aficamten In SEQUOIA-HCM Phase 3 Trial (Upgrade)
- Cytokinetics: Buyout Rumors Ahead Of The Key Phase 3 Readout Of Aficamten
- UBS cuts Cytokinetics to neutral, sees takeout valuation at $105
- Amgen may be evaluating Cytokinetics bid; CYTK wants $130-$145 a share - report (update)
Read the full article on Seeking Alpha
For further details see:
Cytokinetics announces resignation of Ching W. Jaw as chief financial officer